20:34 , Apr 27, 2018 |  BC Week In Review  |  Financial News

Mereo postpones NASDAQ listing

Mereo BioPharma Group plc (LSE:MPH) said on April 26 it postponed an offering to list its ADSs on NASDAQ and withdrew a concurrent placing, citing market conditions. According to an April 9 SEC filing, the...
20:05 , May 12, 2017 |  BC Week In Review  |  Clinical News

Mereo starts Phase IIb for osteogenesis imperfecta

Mereo BioPharma Group plc (LSE:MPH) began the Phase IIb ASTEROID trial to evaluate BPS-804 to treat osteogenesis imperfecta. The double-blind, placebo-controlled, international trial will enroll up to 120 patients to receive 1 of 3 doses...
22:59 , Mar 2, 2017 |  BC Week In Review  |  Clinical News

BPS-804 regulatory update

EMA selected for its adaptive pathways program BPS-804 from Mereo to treat osteogenesis imperfecta (OI). The human mAb inhibiting sclerostin has Orphan Drug designation in the U.S. and EU and has completed Phase II testing...
07:00 , Aug 3, 2015 |  BC Week In Review  |  Company News

Novartis, Mereo BioPharma deal

Start-up Mereo acquired three Phase II compounds from Novartis in exchange for an undisclosed equity stake. Novartis is eligible for milestone payments and royalties. BPS-804 is a human mAb for the Orphan bone disease osteogenesis...
07:00 , Aug 3, 2015 |  BioCentury  |  Finance

From Phase4 to Mereo

The leadership team behind Phase4 Ventures is branching out from its traditional venture roots to launch newco Mereo BioPharma Group Ltd. , which aims to provide an alternative for pharmas looking to advance mid-stage pipelines...
01:07 , Jul 30, 2015 |  BC Extra  |  Top Story

Mereo raises $119M, acquires three Novartis programs<span class="*Red-type+bold">

Mereo BioPharma Group Ltd. (London, U.K.) debuted on Wednesday with $119 million (L76.7 million) and three clinical-stage programs acquired from Novartis AG (NYSE:NVS; SIX:NOVN). Woodford Investment Management and Invesco Perpetual invested in Mereo; Novartis also...